Kornimate/medical-research-clean huggingface dataset:
antimicrobial photodynamic therapy mediated by papamblue® on chronic periodontal disease

Conditions: Periodontal Diseases

Summary: the elimination of the pathogenic microorganisms of the periodontal pocket is one of the main points for success in periodontal treatment. the objective of this study is to investigate the clinical and antimicrobial effect of papain-mediated photodynamic therapy in the clinical treatment of periodontal disease. twenty patients with chronic periodontitis will be selected. patients will be divided randomly into two groups (n = 10), and the control group will receive conventional periodontal treatment and group ii will receive conventional treatment and antimicrobial photodynamic therapy (apdt). conventional treatment will consist of oral hygiene guidance, with brushing technique instructions and recommendation of daily flossing. the calculus deposits on the teeth will be removed with ultrasound equipment and curettes for scraping and root planing. the apdt will be performed at the end of each periodontal treatment session, at sites with bags greater than or equal to 4 mm. the papamblue® photosensitizer will be deposited in the periodontal pockets with a syringe and a pre-irradiation time of 1 min will be adopted. then, the laser emitting wavelength of 660 nm, with power of 100 mw, for 2 min, radiant exposure of 30 j/cm2 and power density of 250 mw/cm2 will be applied. patients will undergo clinical evaluations before treatment (day 1) and 30, 60 and 90 days after the end of treatment. microbiological evaluations will be made before and 30 days after treatment. the distribution of the data within each group and the homogeneity of the variances will be verified. with this information, the most appropriate statistical test for each evaluation will be used. the sample calculation is based on the literature and the significance level of 5% will be adopted.


Eligibility criteria:
inclusion criteria: * the patient must have chronic periodontitis (aap, 2001); * at least 10 present teeth, with at least 3 sites with clinical depth of probing greater than 4 mm; * the patient must be in periodontal treatment at the dental clinic of universidade nove de julho, institution where this research will be carried out; exclusion criteria: * smokers or former smokers who discontinued the habit less than 12 months prior to selection; * uncontrolled diabetes; * anemia; * cancer; * pregnant women; * use of antibiotics in the last 6 months; * use of anti-inflammatory in the last 3 months; * coagulation disorder (use of anti-coagulant, presence of liver diseases, thrombocytopenia and immunosuppression); * patients under orthodontic treatment; * patients who maintain a biofilm index greater than 25%.
the effect of using the combat attention app on the risk of post-traumatic symptoms

Conditions: PTSD - Post Traumatic Stress Disorder

Summary: military service and reserve duty in combat units entails exposure to traumatic events that require mental adjustment. in light of the results of controlled studies that proved the effectiveness an response-time based mechanized training protocol in reducing risk for post-trauma symptoms in deployed combat soldiers, the israeli defense forces decided at the beginning of the iron swords war to implement an internet-based app of the intervention. soldiers and combat reservists were invited to use the combat attention app. the purpose of this study is to examine the effectiveness of the combat attention app in relation to a control group of soldiers who did not use the app in reducing risk for post-traumatic stress symptoms of deployed soldiers.

participants who used the combat attention app before combat deployment and a group of matched (age and sex) participants who did not use the app will be compared on ptsd, depression, and anxiety symptoms post deployment.

Eligibility criteria:
inclusion criteria: * age over 18 years. * served as an enlisted soldier or reservist during the iron swards war. * used the combat attention app or can serve as a matched control who did not use the app. * colloquial hebrew sufficient to fill out the research questionnaires. exclusion criteria: * below 18 years of age. * colloquial hebrew that is insufficient to fill out the research questionnaires.
study of arq 197 monotherapy

Conditions: Gastric Cancer

Summary: a phase ii open-label study with arq 197 administered orally and twice daily as monotherapy in patients with previously treated advanced/recurrent gastric cancer. the primary endpoint is disease control and the secondary efficacy endpoints include antitumor effect (tumor response), progression-free survival and overall survival. the pharmacokinetic profile and the safety profile are also evaluated.


Eligibility criteria:
inclusion criteria: * japanese or korean with voluntary written informed consent for study participation * a histologically or cytologically confirmed advanced/recurrent gastric cancer * one or two prior chemotherapy regimens for advanced/recurrent gastric cancer * at least one measurable lesion * ecog performance status of 0 or 1 * life expectancy ≥3 months exclusion criteria: * surgery for cancer within 4 weeks prior to the first dose of arq 197 * confirmed other tumors than gastric cancer within 5 years prior to the first dose of arq 197 * anticancer chemotherapy, hormone therapy, radiotherapy or immunotherapy within 2 weeks prior to the first dose of arq 197 * positive for hiv antibody * known symptomatic brain metastasis * gastrointestinal disorders that could interfere with the absorption of arq 197 or operation history for gastrointestinal disorders * uncontrolled concomitant disease * patients who wish to have a child and who would not agree to use contraceptive measures * pregnant or lactating

Keywords: advanced/recurrent gastric cancer
slowly digestible carbohydrates and the ileal brake

Conditions: Obesity; Diabetes Mellitus, Type 2; Appetitive Behavior

Summary: the ileal brake is a feedback mechanism controlling stomach-mediated transit of a meal, for which gastric emptying can be used as an indicator. previously, slowly digestible carbohydrates (sdcs) were shown to activate the ileal brake in a rat model; the current research aimed to determine the effect of common sdcs in humans.

diets containing slowly digestible carbohydrates (sdcs), in the form of starch-entrapped microspheres that digest into the ileum, were previously shown to reduce food intake in a diet-induced obese rat model by activating the gut-brain axis. these results suggested that sdcs trigger the ileal brake, which is a feedback mechanism controlling stomach-mediated transit of a meal. the ileal brake is characterized by delayed gastric emptying rate and increased satiety. the goal of this work was to determine if common sdcs trigger the ileal brake in humans, using gastric emptying rate as a proxy indicator. in a human study, sdcs were delivered through a semi-solid yogurt matrix, and gastric half-emptying time and postprandial glycemic response were assessed. the study was a five-arm, double-blind, crossover design with a one-week washout period between treatments (n=20, 9 females, 11 males). four different carbohydrate ingredients (sdcs: isomalto-oligosaccharides (imo), xtend® sucromalt, and raw corn starch; and non-sdc: maltodextrin) were incorporated individually, or in combination, into yogurt products matched in energy density and viscosity. participants consumed 300 g test meals of yogurt formulated with one or a combination of the carbohydrate ingredients after an overnight fast. gastric emptying rates and glycemic response were measured using a 13c-labeled octanoic acid breath test and continuous glucose monitors, respectively. glucose readings were continuously monitored 24 h prior to and 48 h after test meal consumption, and breath samples were collected for a 4 h period following test meal consumption.

Eligibility criteria:
inclusion criteria: * bmi 18.5 - 25 kg/m2 * stable weight for the past 3 months (i.e. +/- 2..5 kg) * regular eating patterns, including breakfast consumption exclusion criteria: * gastrointestinal disease * smokers * peri- or post-menopausal women * celiac disease (yogurts may contain ingredients with wheat origin) * allergies, including dairy, lactose, and gluten * pregnant and lactating women * following a weight reduction program or having followed one during the last 3 months * acute or chronic disease * alcohol consumption \> 30 units/week * hypertension * diabetes * previous bariatric surgery
vein health - cvd prevalence and characteristics

Conditions: Chronic Venous Disease

Summary: epidemiology study to learn prevalence and characteristics of cvd at primary and specialized healthcare level

cross sectional study that will evaluate prevalence, characteristics, diagnostic and treatment status of the patients with chronic venous disease at primary or specialized healthcare level during 2 week period. no interventions are made. information on patient demographic, physical, clinical parameters, medical history data and procedures performed during visit in routine daily practice of physicians is registered and analyzed.

Eligibility criteria:
inclusion criteria: * age above 18 years * patient consented to participate exclusion criteria: * patient applying due to emergency situation

Keywords: chronic venous disease prevalence characteristics management tactics evaluation risk-factors distribution of ceap stages
phosphate binder-combination study of khk7791 in hyperphosphatemia patients

Conditions: Hyperphosphatemia

Summary: to evaluate the effect and safety of khk7791 in combination with phosphate binders to treat hyperphosphatemia in ptatients on hd.


Eligibility criteria:
inclusion criteria: * patients with stable chronic renal failure who have undergone hemodialysis three times per week for at least 12 weeks until screening examination. * dialysis conditions (dialysate, dialyzer, frequency of dialysis per week, dialysis duration, blood flow rate, and dialysate and substitution fluid flow rates), excluding dry weight, should have been unchanged during the last 2 weeks before screening examination. * taking phosphate binders three times per day. the prescribed drug and dosage regimen should have been unchanged during the last 2 weeks before screening examination. * serum phosphorus levels should be in the range of ≥6.1 and ≤10.0 mg/dl at screening examination. * if on any vitamin d or calcimimetics regimen, then the prescribed drug and dosage regimen should have been unchanged for the last 4 weeks before screening examination. exclusion criteria: * ipth \>600 pg/ml (should be based on the most recent value from the patients' medical records, etc. before pre-enrollment) * having concurrent or a history of inflammatory bowel disease (ibd) or diarrhea-predominant irritable bowel syndrome * history of gastrectomy or enterectomy (excluding endoscopic resection and cecectomy) or having undergone gastrointestinal tract surgery within 3 months before screening examination. * having concurrent severe heart disease \[including congestive heart failure, defined as new york heart association (nyha) cardiac functional classification of class iii or iv, and cardiovascular disease requiring hospitalization, such as myocardial infarction\] or hepatic impairment (including ast/alt ≥100 u/l at screening examination, or cirrhosis). * developed cerebrovascular disease (such as cerebral infarction and hemorrhage) or cardiovascular disease (such as myocardial infarction and unstable angina) requiring hospitalization within 6 months before screening examination. * uncontrollable hypertension or diabetes. * scheduled for living donor kidney transplant, change in the mode of dialysis, home hemodialysis, or change in the dialysis center (relocate to another hospital/clinic) during the study period. * any diagnosis of and treatment of malignancy within 5 years before screening examination (excluding basal cell carcinoma or surgically resected intraepithelial carcinoma of uterine cervix).

Keywords: tenapanor hyperphosphatemia hemodialysis
comparison between injection molded polyetheretherketone (peek) framework and cobalt chromium framework removable partial dentures regarding periodontal health of abutment teeth

Conditions: Mandibular Prosthesis User

Summary: this study is aiming to evaluate the periodontal status of the abutment teeth in polyetheretherketone ( peek ) framework partial dentures compared with cobalt-chromium ones in mandibular kennedy class i edentulous cases aiming to preserve the optimum periodontal health of the abutment teeth .


Eligibility criteria:
inclusion criteria: * kennedy class i partially edentulous subjects indicated for framework partial denture exclusion criteria: * 1- uncooperative patients . 2- bad oral hygiene patients .
partial least squares regression modelling for glaucoma detection

Conditions: Glaucoma

Summary: a partial least squares regression model for visual field testing among glaucoma patients will be developed. in addition, microperimetry will be compared to conventional perimetry and reproducibility will be assessed.

aim of this study is to develop a partial least squares regression model incorporating retinal nerve fiber layer (rnfl) and retinal ganglion cell layer (rgcl) measurements as well as visual field testing to represent a glaucoma expert opinion on the stage of glaucoma. in addition, microperimetry will be compared to conventional perimetry and reproducibility will be assessed.

Eligibility criteria:
inclusion criteria: * age 21 and older * written informed consent prior to surgery * any glaucoma-associated changes in one or both eyes (i.e. increased intraocular pressure, optic disc changes, known visual field defects) in the "glaucoma patients" and the absence of any glaucoma associated changes in the "healthy eyes group". exclusion criteria: * secondary glaucoma * in case of pregnancy (pregnancy test will be taken in women of reproductive age)
pharmacokinetics of butyrate tablet bkr-017

Conditions: Hypercholesterolemia

Summary: the purpose of this study is to evaluate the pharmacokinetic profile and systemic exposure of bkr-017 in individuals on statin therapy after a single dose and at steady state after seven days repeated twice daily dosing.

biokier will conduct an open-label study to evaluate the safety and pk profile of bkr-017 in ten hypercholesterolemic (\>100 mg/dl) statin-treated subjects (to reflect the target population), aged 18-70, after a single dose and at steady-state after seven days repeat dosing. on the morning of study day 0, subjects will take three tablets (1.5 g of bkr-017), followed by breakfast. blood samples will be taken for pk analysis at -1, -0.25, 1, 2, 4, 6, 8, 10, 12, and 24 hours after dosing. after an overnight stay in the clinic, the 24-hour pk sample will be taken, and subjects will be provided with one week's supply of bkr-017 tablets and a diary for keeping track of tablets taken, instructed to take three 500-mg tablets (1.5 g) bid, and released from the clinic. on study day 8, subjects will return to the clinic, and study day 0 procedures will be repeated after dose-compliance is confirmed. pk samples will be analyzed.

Eligibility criteria:
inclusion criteria: * men and women, ages 18-70 inclusive * subjects currently on statin treatments. exclusion criteria: * presence of cirrhosis, or other causes of liver disease * substantial alcohol consumption (\>20 g/day for women or \>30 g/day for men) * history of bariatric or intestinal surgery * active gastrointestinal disease including but not limited to irritable bowel syndrome, inflammatory bowel disease (e.g., crohn's disease and ulcerative colitis), diverticulitis, gastroparesis. * active and clinically significant pancreatic disease, or renal disease as determined by the investigator. * history of heart disease that in the opinion of the investigator should exclude the subject from the study. * untreated or uncontrolled hyperthyroidism or hypothyroidism, or other significant thyroid disease * active significant infection as determined by the investigator. * known allergy to butyrate or any of the components of the tablets. * participation in a clinical trial and/or dosing with an investigational drug during the 30 days before screening, or within 5 half-lives of receipt of an investigational drug or twice the duration of the biological effect of any investigational drug (whichever is longer) * pregnant, nursing, or trying to become pregnant. * in the investigator's judgment, the subject is not suitable for the study for any other reason or cannot commit to the requirements of the study. * taking part in another clinical trial or being in the exclusion period of a previous clinical trial.
the effects of flow settings during high flow nasal cannula for adult hypoxemia patients

Conditions: Hypoxemia

Summary: high flow nasal cannula (hfnc) delivers oxygen at a flow which exceeds the patient's inspiratory flow demand in order to improve oxygenation. numerous randomized control trials and meta-analyses have shown that hfnc improves oxygenation and helps avoid intubation in hypoxemic patients, as well as reduce work of breathing, improve ventilation, and decrease hypercapnia in copd patients. flow settings play a critical role when using hfnc, as increased flow can reduce inspiratory effort, improve ventilation, and dynamic lung compliance. however, flow rates used in many studies vary widely. the clinical effects of different hfnc flow setting, specifically to match or over than a patients' own inspiratory flow, is still unknown.

high flow nasal cannula (hfnc) delivers oxygen at a flow which exceeds the patient's inspiratory flow demand in order to improve oxygenation. numerous randomized control trials and meta-analyses have shown that hfnc improves oxygenation and helps avoid intubation in hypoxemic patients, as well as reduce work of breathing, improve ventilation, and decrease hypercapnia in copd patients. flow settings play a critical role when using hfnc, as increased flow can reduce inspiratory effort, improve ventilation, and dynamic lung compliance. however, flow rates used in many studies vary widely, from 20-40 lpm in copd patients and 30-60 lpm in hypoxemic patients. the clinical effects of different hfnc flow setting, specifically to match or over than a patients' own inspiratory flow, is still unknown.

Eligibility criteria:
inclusion criteria: adult patients (age \> 18yrs and \< 90yrs) who need nasal cannula oxygen flow ≥ 5 l/min to maintain spo2 at 90-97%. exclusion criteria (common): - unable to use resuscitation mask, such as facial trauma, claustrophobia * inability to verbally communicate; * pregnant * inability to breathe via nose, such as nasosinusitis, stuffy nose or nasal obstruction, etc. * ordered spo2 goal is above 97% * fio2 needs ≤ 0.4 * using inhaled pulmonary vasodilator via hfnc

Keywords: high flow nasal cannula hypoxemia flow setting
cervical rippening with antiprogesterone in midtrimester abortions

Conditions: Abortion, Missed

Summary: induction of midtrimester abortion includes cervical ripening and then contraction to induce uterine evacuation. there are several protocols, but most of them include using prostaglandins (pg). the disadvantages of using pg include uncomfortable side effects and limits of using it for women after cesarean section. mifepristone is an antiprogesterone drug and been used for induction of abortion in first and second trimesters abortions. the aim of this study is to explore the effectiveness of mifepristone for cervical ripening before high dose oxytocin drip.

the aim of this study is to explore the effectiveness of mifepristone for cervical ripening before high dose oxytocin drip in midtrimester abortions. after informed consent, all the women will be randomized for mifepristone or placebo. 48 hours later, high dose oxytocin drip will be started and we will examine the success rate to induce abortion, the duration from starting oxytocin till evacuation of uterus and side effects.

Eligibility criteria:
inclusion criteria: * midtrimester late abortion * midtrimester induced abortion exclusion criteria: * placenta previa * infected abortion * rupture of membranes * s/p cesarean section \*2 or more
mp-1 biofeedback: pattern stimulus versus audio-feedback in amd

Conditions: Age Related Macular Degeneration

Summary: background: biofeedback techniques have demonstrated their uselfulness in the treatment of maculopathies. we wanted to evaluate the efficacy of visual rehabilitation by means of two different types of biofeedback techniques in patients with age related macular degeneration (amd). methods: 30 patients bilaterally affected by amd were enrolled with a mean age of 76,38±8,77 yrs. patients were randomly divided in two groups: group a was treated with an acoustic biofeedback, group b with luminous biofeedback of a black and white checkerboard flickering during the examination. all patients underwent a complete ophthalmological examination. rehabilitation consisted in 12 training sessions of 10 minutes for each eye performed once a week for both groups. statistical analysis was performed using t- test. p values less than 0.05 were considered statistically significant. results: group a: visual acuity at the end of rehabilitation had improved, but this result was not statistically significant (p=0.054), reading speed showed a significant statistical improvement (p=0.031), as well as the fixation stability (p=0.0023) and single point mean retinal sensitivity value (p=0.044). group b: visual acuity improvement at the end of rehabilitation was statistically significant (p=0.048), reading speed showed a statistically significant improvement (p=0.024), as well as fixation stability (p=0.0012) and mean single point retinal sensitivity value (p=0.027). final results for both groups were compared and patients in group b showed results which were statistically more significant. conclusion: a contrast rich flickering biofeedback stimulus showed a statistically significant improvement in training the patients to modify their preferred retinal locus (prl) in comparison to acoustic biofeedback. it is possible that increased involvement of the various retinal cell populations with visual stimuli create more efficient ganglion cell response that better utilize the residual retinal function.


Eligibility criteria:
inclusion criteria: * we enrolled 30 patients (18 women and 12 men), ranging in age from 56-89 with a mean of 76.38 ±8.77, bilaterally affected by neovascular amd from the medical retina unit of the department of ophthalmology, university la sapienza of rome, polo pontino, a. fiorini hospital from august 2009 to july 2010. diagnosis of neovascular amd was based on a complete ophthalmological examination including anterior and posterior segment biomicroscopy, fluorescein angiography (heidelberg hra2 fa module heidelberg germany), spectral domain oct (heidelberg hra-2 oct module heidelberg germany), microperimetry with mp-1 (nidek technologies padua italy). exclusion criteria: * patients with other eye diseases (i.e. glaucoma, myopia, retinal detachment, etc), uncooperative patients and patients with media opacities were excluded.